Literature DB >> 12435795

Characterization of two pharmacophores on the multidrug transporter P-glycoprotein.

Alexia Garrigues1, Nicolas Loiseau, Marcel Delaforge, Jacques Ferté, Manuel Garrigos, François André, Stéphane Orlowski.   

Abstract

The multidrug transporter P-glycoprotein is a plasma membrane protein involved in cell and tissue detoxification and the multidrug resistance (MDR) phenotype. It actively expels from cells a number of cytotoxic molecules, all amphiphilic but chemically unrelated. We investigated the molecular characteristics involved in the binding selectivity of P-glycoprotein by means of a molecular modeling approach using various substrates combined with an enzymological study using these substrates and native membrane vesicles prepared from MDR cells. We determined affinities and mutual relationships from the changes in P-glycoprotein ATPase activity induced by a series of cyclic peptides and peptide-like compounds, used alone or in combination. Modeling of the intramolecular distribution of the hydrophobic and polar surfaces of this series of molecules made it possible to superimpose some of these surface elements. These molecular alignments were correlated with the observed mutual exclusions for binding on P-glycoprotein. This led to the characterization of two different, but partially overlapping, pharmacophores. On each of these pharmacophores, the ligands compete with each other. The typical MDR-associated molecules, verapamil, cyclosporin A, and actinomycin D, bound to pharmacophore 1, whereas vinblastine bound to pharmacophore 2. Thus, the multispecific binding pocket of P-glycoprotein can be seen as sites, located near one another, that bind ligands according to the distribution of their hydrophobic and polar elements rather than their chemical motifs. The existence of two pharmacophores increases the possibilities for multiple chemical structure recognition. The size of the ligands affects their ability to compete with other ligands for binding to P-glycoprotein.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12435795     DOI: 10.1124/mol.62.6.1288

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  24 in total

1.  Recognition of sulfonylurea receptor (ABCC8/9) ligands by the multidrug resistance transporter P-glycoprotein (ABCB1): functional similarities based on common structural features between two multispecific ABC proteins.

Authors:  Anis Bessadok; Elisabeth Garcia; Hélène Jacquet; Solenne Martin; Alexia Garrigues; Nicolas Loiseau; François André; Stéphane Orlowski; Michel Vivaudou
Journal:  J Biol Chem       Date:  2010-11-22       Impact factor: 5.157

2.  A novel MDR1 GT1292-3TG (Cys431Leu) genetic variation and its effect on P-glycoprotein biologic functions.

Authors:  Matthew H Crouthamel; Daniel Wu; Ziping Yang; Rodney J Y Ho
Journal:  AAPS J       Date:  2010-07-10       Impact factor: 4.009

3.  Lack of Influence of Substrate on Ligand Interaction with the Human Multidrug and Toxin Extruder, MATE1.

Authors:  Lucy J Martínez-Guerrero; Mark Morales; Sean Ekins; Stephen H Wright
Journal:  Mol Pharmacol       Date:  2016-07-14       Impact factor: 4.436

4.  Total synthesis of ningalin D.

Authors:  Akiyuki Hamasaki; Jeffrey M Zimpleman; Inkyu Hwang; Dale L Boger
Journal:  J Am Chem Soc       Date:  2005-08-03       Impact factor: 15.419

5.  Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.

Authors:  Grégoire Dirson; Christine Fernandez; Patrick Hindlet; Françoise Roux; Michèle German-Fattal; François Gimenez; Robert Farinotti
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

6.  De novo prediction of p-glycoprotein-mediated efflux liability for druglike compounds.

Authors:  Hakan Gunaydin; Matthew M Weiss; Yaxiong Sun
Journal:  ACS Med Chem Lett       Date:  2012-11-06       Impact factor: 4.345

7.  Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2.

Authors:  Jaclyn N Harper; Stephen H Wright
Journal:  Am J Physiol Renal Physiol       Date:  2012-10-03

8.  In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier.

Authors:  Salvatore Cisternino; Christophe Rousselle; Marcel Debray; Jean-Michel Scherrmann
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

9.  Substrate-dependent ligand inhibition of the human organic cation transporter OCT2.

Authors:  Mathew Belzer; Mark Morales; Bhumasamudram Jagadish; Eugene A Mash; Stephen H Wright
Journal:  J Pharmacol Exp Ther       Date:  2013-05-24       Impact factor: 4.030

Review 10.  Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators.

Authors:  Ahmad R Safa
Journal:  Curr Med Chem Anticancer Agents       Date:  2004-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.